| Mar 3, 2026 | Alveus Therapeutics | $197.0M Series A Extension | Andera Partners, New Rhein Healthcare Investors | Avego Bioscience Capital, Rafaèle Tordjman, Kurma Partners, Novo Holdings, Omega Funds, Sanofi Ventures |
| Sep 1, 2025 | Odyssey Therapeutics | $210.0M Series D | — | Dimension Capital, General Catalyst, OrbiMed, SR One, Third Rock Ventures, Rafaèle Tordjman, Shelley Chu, Paulina Hill, Carolyn Ng, Affinity Asset Advisors, Wedbush Healthcare Partners |
| May 1, 2025 | Azafaros | $150.0M Series B | Julien ELRIC | Edward Van Wezel, BGV (BioGeneration Ventures), Forbion, Pictet Alternative Advisors, Schroders Capital, Seroba Life Sciences |
| May 1, 2025 | ReproNovo | $65.0M Series A | M Ventures (Merck), Ksenija Pavletic | EQT Life Sciences, Soffinova Partners, Guillem Laporta, CFA, ALSA Ventures, Zina Affas Besse |
| Mar 24, 2025 | Augustine Therapeutics | $91.4M Series A | Clara Campàs, Annette Clancy, Marie Schroeder | — |
| Jan 7, 2025 | XyloCor Therapeutics | $67.5M Series B | Jeito Capital | — |
| Nov 12, 2024 | Alentis Therapeutics | $181.4M Series D | Jeito Capital, Novo Holdings, OrbiMed | — |
| Jan 1, 2024 | HI-Bio | $95.0M Bio - Series B | Chris Dimitropoulos | ARCH Venture Partners, Arkin Bio Ventures, Viking Global Investors |
| Nov 16, 2023 | NMD Pharma | $81.4M Series B | Sabine Dandiguian | INKEF Capital, Lundbeckfonden BioCapital, Novo Holdings, Roche |
| Nov 14, 2023 | Eyebiotech | $65.0M Series A Extension | Michael Ross, Andreas Wallnofer | Bain Capital Life Sciences, MRL Ventures Fund, Bernard Davitian, Samsara BioCapital, SV Health Investors, Christine Brennan |
| Sep 1, 2023 | Corteria Pharmaceuticals | $70.0M Series A | Rafaèle Tordjman, Erez Chimovits | Caixa Capital, Faber, Kurma Partners, Roche Venture Fund, Sanofi Ventures, Fountain Healthcare Partners, Invivo Capital, Omnes Capital, V-Bio Ventures |
| Apr 13, 2023 | Alentis Therapeutics | $105.0M Series C | Jeito Capital, Novo Holdings | — |
| Dec 1, 2022 | Pulmocide | $52.0M Series C | — | Adjuvant Capital, Asahi Kasei Pharma, Cystic Fibrosis Foundation, F-Prime Capital, Sabine Dandiguian, Johnson & Johnson Innovation, Longwood Fund, Pictet Alternative Advisors, SR One, SV Health Investors, Vivo Capital |
| Nov 1, 2022 | CatalYm | $52.0M Series C | Brandon Capital, Rafaèle Tordjman | Albion VC, Bayern Kapital, Oscar Slotboom, BGV (BioGeneration Ventures), Brandon Capital Partners, Canaan Partners, Forbion, Novartis Venture Fund, Red Tree Venture Capital, Soffinova Partners, SV Health Investors |
| Oct 1, 2022 | HI-Bio | $120.0M Bio - Series A | — | ARCH Venture Partners, Rachel Mears, Fred Cohen |
| Sep 1, 2022 | SparingVision | $75.0M Series B | Sabine Dandiguian, Jeanne Cunicelli | 4BIO Capital, Bpifrance, Rusty Kelley, Stephane Boissel, Ysios Capital |
| Apr 13, 2022 | Jeito Capital | $76.0M Series A | Rafaèle Tordjman, Dan Marks | Claudio Nessi |
| Apr 1, 2022 | CDR-Life AG | $76.0M Life AG - Series A | Rafaèle Tordjman, Dan Marks | RA Capital, Claudio Nessi |
| Mar 1, 2022 | Precirix | $88.0M Series B | Forbion, INKEF Capital, Sabine Dandiguian | Aglaia BioMedical Ventures, Keno Gutierrez, Novartis Venture Fund, Pfizer Venture Investments, Pontifax Venture Capital, BioMedPartners, Gimv, HealthCap, Novo Holdings, V-Bio Ventures |
| Feb 15, 2022 | NMD Pharma | $39.6M Other Equity | Sabine Dandiguian | Roel Bulthuis, Lundbeckfonden, Novo Holdings, Roche |
| Feb 1, 2022 | Eyebiotech | $65.0M Series A | Michael Ross | Abingworth, Bain Capital Life Sciences, MRL Ventures Fund, RiverVest, SV Health Investors, Mott Family Capital, Omega Funds, Andreas Wallnoefer, Srinivas Akkaraju |
| Nov 1, 2021 | Quell Therapeutics | $160.0M Series B | Fidelity Management & Research Company, Rachel Mears, Wayne Holman, Houman Ashrafian | Lightstone Ventures, Soffinova Partners, SV Health Investors, Judith Hartley MBE, Janus Henderson Investors, Monashee Investment Management, Point72, Martin Murphy, Tekla Capital Management |
| May 1, 2021 | Pulmocide | $92.0M Series C | Sabine Dandiguian | Adjuvant Capital, Asahi Kasei Pharma, F-Prime Capital, Johnson & Johnson Innovation, Longwood Fund, SR One, SV Health Investors |
| Dec 1, 2020 | Innoskel | $24.0M Series A | Vida Ventures, Rafaèle Tordjman | Turenne Capital |
| Oct 1, 2020 | SparingVision | $53.0M Series A | 4BIO Capital, UPMC Enterprises | Bpifrance, Foundation Fighting Blindness, Sabine Dandiguian, Karen Wagner |
